Hi, I may be missing something(very possible) but I thought the company was working on phase two for cyt387.Now I find out they have not even started yet? Could this be the reason for the price decline????...Thanks, Barry
Read this: lifted right off recent filing. Make up your mind. Either you are in or out.
“The favorable safety profile of CYT387 observed to date provides us with the opportunity to acquire further safety and efficacy data for CYT387 at doses complementary to those evaluated in our ongoing 166 patient Phase I/II trial,” said Dr. Nick Glover, President and CEO of YM BioSciences. “Initial data from the BID trial will be used to further enhance our pivotal trial designs, and the substantial volume of patient data from the combined studies will be an important component of any future marketing application
I just thought I read somewhere that they were going to report trial in Dec. If they are just starting is that feasable? I don't want to sound like a basher, I own a small pos compared to some out here...Barry
The existing phase I/II trial has been yielding positive results. The new trial is to further explore dosing options and obtain more detailed and precise data on patient response. For example, MRI will be used to measure spleen size.
Ya they better measure spleen size. THey never thought of that in the original trial. Big screw up now they have to essential start over. 1.2 is my new target! This is why small bio techs get taken to the cleaner because they have limited funds and try to cut coners. Case in point is on big screw up in Europe two years ago. They hired a third party vendor to oversee trials. It was essential some fat nurse eating bon bons and collecting a nice big pay check. The Europe regulators fund a zillion errors and said redue trial! I think this was the precious lung data! Will they ever learn? Bo they don't have to because they print stock certificates. I still have puts!